Cargando…
Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study
BACKGROUND: Oral 5-aminosalicylic acid (5-ASA) is the mainstay treatment of ulcerative colitis (UC) and therapy with oral 5-ASA is associated with beneficial outcomes. We have examined factors associated with the persistence of oral 5-ASA treatment in a national cohort of UC patients. METHODS: Patie...
Autores principales: | Fossmark, Reidar, Olaisen, Maya, Martinsen, Tom Christian, Melberg, Hans Olav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243103/ https://www.ncbi.nlm.nih.gov/pubmed/34262610 http://dx.doi.org/10.1177/17562848211021760 |
Ejemplares similares
-
Mucosal 5‐aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis
por: Olaisen, Maya, et al.
Publicado: (2019) -
Reply to “Too Soon to Dismiss Inflammation-Related Differences in the
Mucosa-Associated Microbiota in Crohn’s Disease Patients”
por: Olaisen, Maya, et al.
Publicado: (2022) -
Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis
por: Tripathi, Kartikeya, et al.
Publicado: (2021) -
Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn’s Disease
por: Olaisen, Maya, et al.
Publicado: (2020) -
5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
por: Miyoshi, Jun, et al.
Publicado: (2018)